Pulmonary hypertension Phase II progress for Novartis and Bayer Schering
This article was originally published in Scrip
Positive preliminary Phase II findings for two novel pulmonary hypertension (PH) treatments, Bayer Schering Pharma'sfirst-in-class vasodilator riociguat (BAY 63-2521) and Novartis's oncology drug Glivec (imatinib) were presented at the recent European Respiratory Society congress in Berlin, Germany.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.